ClinicalTrials.gg
RecruitingNCT07838220Updated Sep 24, 2026

A Study of IBI3016 in Japanese Participants

A Phase 1 interventional study of IBI3016 Dose 4 and IBI3016 Dose 3 in Hypertension, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Hypertension with a site in Japan — 11 open to participants now, 17 under way, 8 of them phase 3. Hypertension · Japan.

Planned enrollment
112th of 125
30 · median 237
Started
2026
with 4 others
Phase 1
7 of 142
2 open now
Primary completion
2027-01
later than 3 of 16 live
Registered
141st of 142
by date

Among the 142 studies in Hypertension with a site in Japan, this one is the 112th largest by planned enrollment of the 125 interventional ones that give a count, is one of 5 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 3 of the 16 other live ones, and was the 141st registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

11 of the 142 studies in Hypertension with a site in Japan are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hypertension with a site in Japan, or all of them as a file.
02

Study summary

A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male or female participants aged 18-75 years (inclusive) at the time of ;
  • 2. Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin;
  • 3. Office mean sitting SBP≥ 140 mmHg and \< 170 mmHg at screening

Exclusion criteria

Exclusion Criteria:

  • 1. Participants with secondary hypertension, including but not limited to the following conditions: obstructive sleep apnea;
  • 2. History of orthostatic hypotension
  • 3. Current or history of intolerance to AECI, ARB, ARNI or direct renin inhibitor
  • 4. With diseases that require treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors other than hypertension at screening;
  • 5. Presence of serious active and uncontrolled physical conditions or medical history, which may be in a dangerous state during the use of the study drug, or interfere with the interpretation of efficacy and safety data of this study, as judged by the investigator prior to randomization
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    IBI3016 Dose1

    single doses of IBI3016 administered by subcutaneous injection

    Drug: IBI3016 Dose 1

  • Experimental
    IBI3016 Dose 2

    single doses of IBI3016 administered by subcutaneous injection

    Drug: IBI3016 Dose 2

  • Experimental
    IBI3016 Dose4

    single doses of IBI3016 administered by subcutaneous injection

    Drug: IBI3016 Dose 4

  • Placebo comparator
    Placebo

    single doses of Placebo administered by subcutaneous injection

    Drug: Placebo

  • Experimental
    IBI3016 Dose3

    single doses of IBI3016 administered by subcutaneous injection

    Drug: IBI3016 Dose 3

Interventions

  • single doses of IBI3016 administered by subcutaneous injection

  • single doses of IBI3016 administered by subcutaneous injection

  • single doses of IBI3016 administered by subcutaneous injection

  • single doses of IBI3016 administered by subcutaneous injection

  • DrugPlacebo

    single doses of IBI3016 administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    Time frame: Through 24 weeks, up to approximately 12 months

Secondary outcomes

  1. Plasma Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI3016

    Time frame: Predose, early post-dose and up to 48 hours postdose

  2. Plasma PK: Area Under the Concentration Versus Time Curve (AUC) of IBI3016

    Time frame: Predose, Day 1, and up to 48 hours postdose

  3. Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) assessed by OBP and ABPM

    Time frame: Baseline, Month 3 and Month 6

  4. Change from baseline in serum angiotensinogen (AGT) concentration

    Time frame: Through 24 weeks, up to approximately 12 months

  5. Urine PK parameter: drug accumulation

    Time frame: Predose, Day 1, and up to 48 hours postdose

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 5 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2026
First posted
Sep 24, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Nov 5, 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07838220
Responsible party
Sponsor
First posted
Sep 24, 2026
Start date
Aug 1, 2026
Primary completion
Jan 30, 2027 (estimated)
Completion
Nov 5, 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

Wendy Duan
Contact
wenjing.duan@innoventbio.com
+86 010-87412310
Congying Xia
Contact
congying.xia@innoventbio.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3016

Start the discussion